دورية أكاديمية
Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial
| العنوان: | Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial |
|---|---|
| المؤلفون: | Dijkstra, Esmée, Hospers, Geke, Meershoek-Klein Kranenbarg, Elma, Fleer, Joke, Roodvoets, Annet, Bahadoer, Renu Ragini, Capdevila Castillon, Jaume |
| المساهمون: | Institut Català de la Salut, Dijkstra EA, Hospers GAP Department of Medical Oncology, University Medical Center Groningen, University of Groningen, the Netherlands. Kranenbarg EMK, Roodvoets AGH, Bahadoer RR Department of Surgery, Leiden University Medical Center, the Netherlands. Fleer J Department of Health Sciences, Section Health Psychology, University Medical Center Groningen, University of Groningen, the Netherlands. Capdevila J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Recte - Càncer - Quimioteràpia, Recte - Càncer - Radioteràpia, Pacients - Satisfacció, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Rectal Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Chemoradiotherapy, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy, HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales::neoplasias del recto, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::quimiorradioterapia, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante, ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida |
| الوصف: | Locally advanced rectal cancer; Quality of life; Total neoadjuvant treatment ; Cáncer de recto localmente avanzado; Calidad de vida; Tratamiento neoadyuvante total ; Càncer de recte localment avançat; Qualitat de vida; Tractament neoadjuvant total ; Background and purpose The RAPIDO trial demonstrated a decrease in disease-related treatment failure (DrTF) and an increase in pathological complete responses (pCR) in locally advanced rectal cancer (LARC) patients receiving total neoadjuvant treatment (TNT) compared to conventional chemoradiotherapy. This study examines health-related quality of life (HRQL), bowel function, and late toxicity in patients in the trial. Materials and methods Patients were randomized between short-course radiotherapy followed by pre-operative chemotherapy (EXP), or chemoradiotherapy and optional post-operative chemotherapy (STD). The STD group was divided into patients who did (STD+) and did not (STD−) receive post-operative chemotherapy. Three years after surgery patients received HRQL (EORTC QLQ-C30, QLQ-CR29 and QLQ-CIPN20) and LARS questionnaires. Patients who experienced a DrTF event before the toxicity assessments (6, 12, 24, or 36 months) were excluded from analyses. Results Of 574 eligible patients, 495 questionnaires were returned (86%) and 453 analyzed (79% completed within time limits). No significant differences were observed between the groups regarding QLQ-C30, QLQ-CR29 or LARS scores. Sensory-related symptoms occurred significantly more often in the EXP group compared to all STD patients, but not compared to STD+ patients. Any toxicity of any grade and grade ≥ 3 toxicity was comparable between the EXP and STD groups at all time-points. Neurotoxicity grade 1–2 occurred significantly more often in the EXP and STD+ group at all time-points compared to the STD− group. Conclusion The results demonstrate that TNT for LARC, yielding improved DrTF and pCRs, does not compromise HRQL, bowel functional or results in more grade ≥3 toxicity compared to standard chemoradiotherapy at ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0167-8140 |
| العلاقة: | Radiotherapy and Oncology;171; https://doi.org/10.1016/j.radonc.2022.04.013Test; Dijkstra EA, Hospers GAP, Kranenbarg EMK, Fleer J, Roodvoets AGH, Bahadoer RR, et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial. Radiother Oncol. 2022 Jun;171:69–76.; https://hdl.handle.net/11351/9660Test; 000795747700010 |
| DOI: | 10.1016/j.radonc.2022.04.013 |
| الإتاحة: | https://doi.org/10.1016/j.radonc.2022.04.013Test https://hdl.handle.net/11351/9660Test |
| حقوق: | Attribution-NonCommercial-NoDerivatives 4.0 International ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.40D32FD2 |
| قاعدة البيانات: | BASE |
| تدمد: | 01678140 |
|---|---|
| DOI: | 10.1016/j.radonc.2022.04.013 |